Home › NDC Lookup › Ingredients › Nystatin › 68382-0370-02
🧂image loading
(from DailyMed)

NYSTATIN 100000 [USP'U]/g Powder, 30 g — NDC 68382-370-02 (Billing 68382-0370-02)

by Zydus Pharmaceuticals USA Inc. · 30 g in 1 BOTTLE, PLASTIC

This is a package of 30 g of NYSTATIN 100000 [USP'U]/g Powder from Zydus Pharmaceuticals USA Inc., marketed since Oct 2021 and currently FDA-listed; retail pharmacies pay about $0.3134 per g (NADAC).

NDC 68382-0370-02
🏷️ FDA NDC (as labeled) 68382-370-02 billing pads the product segment with a zero
This package
Contains30 g Cost per g$0.3134 NADAC Per package$9.40 / 30 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.4706/unit · Part D plans $0.3744/unit — full pricing hub ↓
Product page 68382-0370-03 Also comes in: 15 g 68382-370-01 60 g 68382-370-03
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Nystatin (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jun 23, 2026 — Subpotent Drug: Low out of specification assay results performed during long-term stability testing. (Padagis US LLC) · FDA recall D-0677-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 68382-370-02
Product NDC 68382-370
11-digit billing NDC 68382037002
NCPDP billing unit GM — per gram (weight)
RxCUI 646456
UNII BDF1O1C72E
UPC 0368382370037, 0368382370013, 0368382370020
Application # ANDA208581
SPL Set ID 2daf159d-6a12-4b5d-97b3-8069c17e7635
Established class (EPC) Polyene Antifungal
Chemical class Polyenes
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-10-06
Route TOPICAL
Dosage form POWDER
Substance NYSTATIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90150080002920
GPI class Nystatin
GCN Seq No 007284
GCN 30160
HICL code 004129
Ingredient (HICL) Nystatin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.28.00
AHFS class Polyene Antifungals
FDB label name NYSTATIN 100,000 UNIT/GM POWD
FDB brand name Nystatin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007284
  • GCN: 30160
  • GPI-14 (Medi-Span): 90150080002920
  • HICL (First Databank): 004129
  • AHFS class code: 08:14.28.00
  • RxCUI (RxNorm): 646456
Why two NDCs? The FDA registers this code as 68382-370-02 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 68382-0370-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Polyene Antifungal class.

Pharmacologic class Polyene Antifungal
Drug family (ATC) Antibiotics, Antibiotics, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NYSTATIN 100,000 UNIT/GM POWD Ingredient Nystatin
📗 Our plain-language guide HelloPharmacist
  • It treats Candida yeast infections. Creams, ointment and powder are for the skin. The liquid is for the mouth. Tablets are for the digestive tract lining.
  • Place half the dose in each side of your mouth and keep it there as long as you can before swallowing. For babies, use the dropper and avoid feeding for 5 to 10 minutes. Keep going...
  • How do I use the liquid for a mouth infection?
  • Cream and ointment are usually applied twice a day. Powders are used two or three times a day. Keep using it until the area has healed, and follow your prescriber’s directions.
📖 Read our full Nystatin guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.313 $9.40 / 30 g
Medicaid paysCMS SDUD · 12 mo $0.4706 $14.12 / 30 g
Medicare drug plans payPart D · Q2 2026 $0.3744 $11.23 / 30 g
NADAC price history (per g) — tap or hover for the price & month
Mar 2022 Oct 2022 Feb 2026 Sep 2026 $0.350 $0.254
▲ Up 1% over the last 22 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
68382-0370-01 68382-370-01 15 g in 1 BOTTLE, PLASTIC $0.4214 / g $6.32 2021-10-06 — Active
68382-0370-02 You're viewing this 30 g in 1 BOTTLE, PLASTIC $0.3134 / g $9.40 2021-10-06 — Active
68382-0370-03 68382-370-03 Main listing 60 g in 1 BOTTLE, PLASTIC $0.2574 / g $15.44 2021-10-06 — Active

You're viewing one of 3 pack sizes for this product.

Per g, this pack runs about 22% above the cheapest pack (60 g, $0.2574 vs $0.3134 NADAC).

This pack accounts for about 22% of this product's recent Medicaid fills; the largest share goes to the 60 gs pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 30 g — 30 g in 1 bottle, plastic.
How does this package differ from NDC 68382-0370-01?
Both are NYSTATIN 100000 [USP'U]/g Powder — the drug itself is identical. This page's package is the 30 g one, while NDC 68382-0370-01 is the 15 g package. Per-g NADAC also differs: $0.3134 here vs $0.4214 for the 15 g pack.
What NDC number is used to bill for this package of NYSTATIN 100000 [USP'U]/g Powder?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nystop 100000 [USP'U]/g 00574-2008-02 Padagis 60 g $0.257 AT Availability likely save 18%
Nystatin Topical Powder 100000 U/g 42806-0178-15 Epic 15 g $0.307 AT FDA listed save 2%
Nystatin 100000 [USP'U]/gthis 68382-0370-02 Zydus 30 g $0.313 AT Availability likely —
Nystatin 100000 [USP'U]/g 75907-0060-30 Dr. 30 g $0.313 AT Availability likely —
Nyamyc 100000 [USP'U]/g 00832-0465-15 Upsher-Smith 1 bottle $0.421 AT Availability likely +34%
Klayesta 100000 U/g 42806-0186-15 Epic 15 g $0.421 AT Availability likely +34%
Nystatin 100000 [USP'U]/g 69315-0306-15 Leading 15 g $0.421 AT Availability likely +34%
Nystatin 100000 [USP'U]/g 72603-0491-01 Northstar 15 g $0.421 AT Availability likely +34%
Nystatin Topical Powder 100000 U/g 42806-0185-15 Epic 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8696-01 Bryant 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8697-01 Bryant 30 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8698-01 Bryant 60 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 70771-1585-01 Zydus 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 71335-2845-01 Bryant 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 71335-2869-01 Bryant 30 g — AT FDA listed —
Nystop 100000 [USP'U]/g 72162-1124-02 Bryant 15 g — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Oct 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Pharmaceuticals USA Inc.
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA208581 (ANDA)
Labeler code68382
First marketedOct 2021
Product typeHuman Prescription Drug
Portfolio454 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 🧬 Pharmacokinetics 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 39 words ▾

INDICATIONS AND USAGE Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. Nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.

⏱️ Dosage and Administration 59 words ▾

DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infections of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.

⛔ Contraindications 18 words ▾

CONTRAINDICATIONS Nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.

🤒 Adverse Reactions 41 words ▾

ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical powder is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS , General .)

🤰 Pregnancy 65 words ▾

Pregnancy Teratogenic Effects Category C Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

🧒 Pediatric Use 22 words ▾

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION .)

🧓 Geriatric Use 55 words ▾

Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

🧬 Clinical Pharmacology 155 words ▾

CLINICAL PHARMACOLOGY Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Trichophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components.

On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well.

This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

📦 How Supplied / Storage and Handling 50 words ▾

HOW SUPPLIED Nystatin topical powder, USP is supplied as 100,000 units nystatin per gram in plastic squeeze bottles: 15 g (NDC 68382-370-01) 30 g (NDC 68382-370-02) 60 g (NDC 68382-370-03) STORAGE Store at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F). Keep tightly closed.

📋 Description 34 words ▾

DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces noursei. Structural formula: Nystatin topical powder is for dermatologic use. Nystatin topical powder contains 100,000 USP nystatin units per gram dispersed in talc. Structure

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Nystatin topical powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out other infection caused by other pathogens.

INFORMATION FOR THE PATIENT Patients using this medication should receive the following information and instructions: The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

If symptoms or irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin.

No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy Teratogenic Effects Category C Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity.

Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mother It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION .) Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

🧬 Pharmacokinetics 11 words ▾

Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane.

📄 Package Label / Principal Display Panel 93 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68382-370-01 Nystatin Topical Powder, USP FOR TOPICAL USE ONLY 100,000 units per gram Rx Only 15 GRAMS Zydus 15 g Bottle Label 15 g Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68382-370-02 Nystatin Topical Powder, USP FOR TOPICAL USE ONLY 100,000 units per gram Rx Only 30 GRAMS Zydus 30 g Bottle Label 30 g Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68382-370-03 Nystatin Topical Powder, USP FOR TOPICAL USE ONLY 100,000 units per gram Rx Only 60 GRAMS Zydus 60 g Bottle Label 60 g Bottle Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
34.2K
Units reimbursed last 4 qtrs
1.3M
Gross reimbursed last 4 qtrs
$590.6K
Avg / prescription
$17.28
Avg / unit
$0.4706
Latest quarter Q4 2025
8.3KRx
Medicaid pays / g
$0.4706
gross reimbursed
vs
NADAC / g
$0.3134
acquisition cost
=
Spread
+$0.1572
+50% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
41% FFS 59% MCO
Fee-for-service · 14,157 Rx Managed care · 20,017 Rx
State Medicaid map
Alaska: 2,700 units · 368 per 100k residents AK Maine: 3,660 units · 262 per 100k residents ME Washington: 52,905 units · 677 per 100k residents WA Idaho: 2,580 units · 131 per 100k residents ID Montana: 2,820 units · 249 per 100k residents MT North Dakota: no data reported ND Minnesota: 12,480 units · 218 per 100k residents MN Wisconsin: 19,908 units · 337 per 100k residents WI Michigan: 40,381 units · 402 per 100k residents MI New York: 33,810 units · 173 per 100k residents NY Vermont: 1,530 units · 236 per 100k residents VT New Hampshire: 3,150 units · 225 per 100k residents NH Oregon: 15,945 units · 377 per 100k residents OR Nevada: 23,805 units · 745 per 100k residents NV Wyoming: 420 units · 71.9 per 100k residents WY South Dakota: 2,134 units · 232 per 100k residents SD Iowa: 10,230 units · 319 per 100k residents IA Illinois: 19,336 units · 154 per 100k residents IL Indiana: 40,192 units · 586 per 100k residents IN Ohio: 69,480 units · 590 per 100k residents OH Pennsylvania: 39,135 units · 302 per 100k residents PA New Jersey: 2,385 units · 25.7 per 100k residents NJ Massachusetts: 19,980 units · 285 per 100k residents MA California: 240,820 units · 618 per 100k residents CA Utah: 10,890 units · 319 per 100k residents UT Colorado: 19,770 units · 336 per 100k residents CO Nebraska: 5,670 units · 287 per 100k residents NE Missouri: 33,840 units · 546 per 100k residents MO Kentucky: 41,775 units · 923 per 100k residents KY West Virginia: 16,680 units · 942 per 100k residents WV Virginia: 37,950 units · 435 per 100k residents VA Maryland: 12,810 units · 207 per 100k residents MD Connecticut: 14,610 units · 404 per 100k residents CT Rhode Island: 2,730 units · 249 per 100k residents RI Arizona: 28,740 units · 387 per 100k residents AZ New Mexico: 9,420 units · 446 per 100k residents NM Kansas: 3,885 units · 132 per 100k residents KS Arkansas: 13,440 units · 438 per 100k residents AR Tennessee: 20,445 units · 287 per 100k residents TN North Carolina: 33,270 units · 307 per 100k residents NC South Carolina: 21,855 units · 407 per 100k residents SC Delaware: 1,560 units · 151 per 100k residents DE Oklahoma: 20,880 units · 515 per 100k residents OK Louisiana: 30,195 units · 660 per 100k residents LA Mississippi: 11,970 units · 407 per 100k residents MS Alabama: 15,898 units · 311 per 100k residents AL Georgia: 31,080 units · 282 per 100k residents GA D.C.: 630 units · 92.8 per 100k residents DC Hawaii: 4,320 units · 301 per 100k residents HI Texas: 83,085 units · 272 per 100k residents TX Florida: 67,775 units · 300 per 100k residents FL
Units reimbursed · per 100k residents
25.7942
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 West Virginia 942 /100k
2 Kentucky 923 /100k
3 Nevada 745 /100k
4 Washington 677 /100k
5 Louisiana 660 /100k
6 California 618 /100k
7 Ohio 590 /100k
8 Indiana 586 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
60 gs68382-0370-03 75,624 Rx · $1,746,146
15 gs68382-0370-01 47,681 Rx · $578,893
30 gs this page68382-0370-02 34,174 Rx · $590,576
Drug total (last 4 qtrs): 157,479 Rx · 7,175,940 units · $2,915,615 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Nystatin — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Nystatin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.29M
Claims incl. refills
853.7K
Beneficiaries
614.3K
Spend / beneficiary
$26.52
Spend / claim
$19.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 68382-0358-01 · Zydus 68382-0383-06 · Zydus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.